Literature DB >> 24335534

Molecular dissection of the VHL gene in solitary capillary hemangioblastoma of the central nervous system.

Lucia Anna Muscarella1, Annamaria la Torre, Augusta Faienza, Demenico Catapano, Michele Bisceglia, Vincenzo D'Angelo, Paola Parrella, Michelina Coco, Grazia Fini, Angelo Tancredi, Leopoldo Zelante, Vito Michele Fazio, Leonardo D'Agruma.   

Abstract

Capillary hemangioblastomas (HGBs) of the CNS occur either sporadically or as part of the von Hippel-Lindau (VHL) syndrome. Molecular characterizations of the VHL gene in sporadic HGBs at the somatic level have been limited to date. We investigated the VHL gene in 57 patients most of whom (55 [96%] of 57) had a solitary CNS HGB at the time of surgery. Tissues from 23 HGBs of these patients (2 VHL related and 21 unrelated) were also investigated at genetic and epigenetic levels. Two of the 51 patients with apparently sporadic HGBs and no additional evidence of VHL (∼4%) were found to have a germline VHL gene mutation; both of these patients subsequently developed evidence of VHL syndrome. Somatic VHL gene mutations were found in 11 (52%) of the 21 non-VHL-related cases. A germline mutation was identified in 5 (84%) of 6 VHL-associated HGBs; double gene inactivation was observed in tumor tissue from VHL syndrome patients. Seven different previously unreported VHL gene alterations (6 somatic and 1 germline) were identified; double hits were identified in 7 (12%) of 57 cases. Our findings confirm the usefulness of VHL gene analysis at the germline level in patients who present with apparently solitary HGB. Moreover, the genetic and epigenetic VHL gene investigations performed support a key role for functional alterations of the VHL gene in sporadic neuraxial HGB.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24335534     DOI: 10.1097/NEN.0000000000000024

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  4 in total

1.  Somatic gain-of-function HIF2A mutations in sporadic central nervous system hemangioblastomas.

Authors:  David Taïeb; Anne Barlier; Chunzhang Yang; Morgane Pertuit; Aurélie Tchoghandjian; Claire Rochette; Hélène Zattara-Canoni; Dominique Figarella-Branger; Zhengping Zhuang; Karel Pacak; Philippe Metellus
Journal:  J Neurooncol       Date:  2015-10-29       Impact factor: 4.130

2.  In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease.

Authors:  Amit Tirosh; Mustapha El Lakis; Patience Green; Pavel Nockel; Dhaval Patel; Naris Nilubol; Sudheer Kumar Gara; Xavier M Keutgen; W Marston Linehan; Electron Kebebew
Journal:  J Clin Endocrinol Metab       Date:  2018-04-01       Impact factor: 5.958

3.  Differences in genetic and epigenetic alterations between von Hippel-Lindau disease-related and sporadic hemangioblastomas of the central nervous system.

Authors:  Shunsaku Takayanagi; Akitake Mukasa; Shota Tanaka; Masashi Nomura; Mayu Omata; Shunsuke Yanagisawa; Shogo Yamamoto; Koichi Ichimura; Hirofumi Nakatomi; Keisuke Ueki; Hiroyuki Aburatani; Nobuhito Saito
Journal:  Neuro Oncol       Date:  2017-09-01       Impact factor: 12.300

Review 4.  Development of Database and Genomic Medicine for von Hippel-Lindau Disease in Japan.

Authors:  Shunsaku Takayanagi; Akitake Mukasa; Hirofumi Nakatomi; Hiroshi Kanno; Jun-Ichi Kuratsu; Ryo Nishikawa; Kazuhiko Mishima; Atushi Natsume; Toshihiko Wakabayashi; Kiyohiro Houkin; Shunsuke Terasaka; Masahiro Yao; Nobuo Shinohara; Taro Shuin; Nobuhito Saito
Journal:  Neurol Med Chir (Tokyo)       Date:  2017-01-06       Impact factor: 1.742

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.